(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.56%.
Kazia Therapeutics's earnings in 2026 is -$16,170,694.On average, 7 Wall Street analysts forecast KZIA's earnings for 2027 to be -$9,698,507,500, with the lowest KZIA earnings forecast at -$11,275,910,713, and the highest KZIA earnings forecast at -$7,974,869,998. On average, 7 Wall Street analysts forecast KZIA's earnings for 2028 to be -$11,953,236,203, with the lowest KZIA earnings forecast at -$17,885,927,338, and the highest KZIA earnings forecast at -$7,498,758,356.
In 2029, KZIA is forecast to generate -$122,995,507 in earnings, with the lowest earnings forecast at -$118,461,111 and the highest earnings forecast at -$126,963,104.